Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,804 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03179410 | PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer(PICK-NEPC) | completed | Phase 2 | 15 | Andrew J. Armstrong, MDOTHER | 1 | Mar 5, 2021 | clinicaltrials |
| NCT02860819 | Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer | completed | Phase 2 | 15 | National Cancer Institute, SlovakiaOTHER_GOV | 1 | Mar 3, 2021 |
| clinicaltrials |
| NCT01610206 | A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer | completed | Phase 2 | 148 | Linda R DuskaOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT01989546 | Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations | completed | Phase 1 / Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2021 | clinicaltrials |
| NCT02172911 | A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer | completed | Phase 1 / Phase 2 | 10 | Inovio PharmaceuticalsINDUSTRY | 1 | Feb 21, 2021 | clinicaltrials |
| NCT03263780 | High Resolution PET-MRI Before Prostate Cancer HIFU | completed | Phase 2 | 21 | Timothy J. DaskivichOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT01146795 | Neoadjuvant Therapy for Ovarian Cancer | completed | Phase 2 | 32 | Jason D. WrightOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT02628041 | HDR Brachytherapy vs. LDR Brachytherapy Monotherapy in Localized Prostate Cancer(HDRvsLDR) | completed | Phase 2 | 30 | CHU de Quebec-Universite LavalOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT02682693 | Denosumab as an add-on Neoadjuvant Treatment (GeparX)(GeparX) | completed | Phase 2 | 780 | GBG Forschungs GmbHOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT02022917 | Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer | completed | Phase 2 | 22 | Chang Gung Memorial HospitalOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT02725489 | Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers | completed | Phase 2 | 13 | Mary Crowley Medical Research CenterOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT01341652 | Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer | completed | Phase 2 | 99 | University of Wisconsin, MadisonOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT01882985 | Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients | completed | Phase 2 | 14 | University of California, IrvineOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT03418324 | Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy | completed | Phase 2 | 11 | Cedars-Sinai Medical CenterOTHER | 1 | Dec 30, 2020 | clinicaltrials |
| NCT03742713 | Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian Cancer(CINOVA) | completed | Phase 2 | 25 | Cristal TherapeuticsINDUSTRY | 3 | Dec 28, 2020 | clinicaltrials |
| NCT02611882 | Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients(PSMA PET) | completed | Phase 2 | 225 | Thomas HopeOTHER | 1 | Dec 22, 2020 | clinicaltrials |
| NCT03348527 | A Study to Evaluate the Safety, Tolerability and Efficacy of a Liproca® Depot Injection in Patients With Prostate Cancer | completed | Phase 2 | 61 | Lidds ABINDUSTRY | 3 | Dec 21, 2020 | clinicaltrials |
| NCT00420381 | Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer | completed | Phase 2 | 28 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT01519869 | Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma | completed | Phase 2 | 28 | Rachel MillerOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT02919111 | Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients(PSMA PreRP) | completed | Phase 2 / Phase 3 | 299 | University of California, San FranciscoOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT01940276 | Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer | completed | Phase 2 | 100 | Duke UniversityOTHER | 1 | Dec 9, 2020 | clinicaltrials |
| NCT02490488 | Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients | completed | Phase 2 / Phase 3 | 248 | AB ScienceINDUSTRY | 6 | Dec 8, 2020 | clinicaltrials |
| NCT00551070 | Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Dec 3, 2020 | clinicaltrials |
| NCT00227721 | Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer | completed | Phase 2 | 30 | Robert MorrisOTHER | 1 | Dec 2, 2020 | clinicaltrials |
| NCT01051570 | Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel | completed | Phase 2 | 26 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 1, 2020 | clinicaltrials |
| NCT02399592 | Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer(Toco-Ovar) | completed | Phase 2 | 23 | Vejle HospitalOTHER | 1 | Nov 30, 2020 | clinicaltrials |
| NCT02093598 | POEM STUDY: A Phase IIa Trial in Endometrial Carcinoma With Temsirolimus(POEM) | completed | Phase 2 | 10 | MedSIROTHER | 1 | Nov 27, 2020 | clinicaltrials |
| NCT00428714 | Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy | completed | Phase 2 | 73 | Eli Lilly and CompanyINDUSTRY | 1 | Nov 25, 2020 | clinicaltrials |
| NCT00436215 | Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Nov 23, 2020 | clinicaltrials |
| NCT02397408 | 11C- and 18F-Choline PET/MR Imaging for Prostate Cancer | completed | Phase 2 | 18 | University of California, San FranciscoOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT02036060 | Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer.(ABIDO) | completed | Phase 2 | 119 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Nov 16, 2020 | clinicaltrials |
| NCT01576172 | Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 159 | National Cancer Institute (NCI)NIH | 1 | Nov 12, 2020 | clinicaltrials |
| NCT03480750 | Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer(Trientine) | completed | Phase 1 / Phase 2 | 18 | National Cheng-Kung University HospitalOTHER | 0 | Nov 10, 2020 | clinicaltrials |
| NCT00466440 | A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients | completed | Phase 2 | 108 | Eli Lilly and CompanyINDUSTRY | 3 | Nov 6, 2020 | clinicaltrials |
| NCT01258998 | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2020 | clinicaltrials |
| NCT00970203 | Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer | completed | Phase 2 | 13 | Roswell Park Cancer InstituteOTHER | 1 | Nov 3, 2020 | clinicaltrials |
| NCT02199197 | Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer | completed | Phase 2 | 49 | University of UtahOTHER | 1 | Oct 30, 2020 | clinicaltrials |
| NCT02283658 | Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 20 | Mayo ClinicOTHER | 1 | Oct 23, 2020 | clinicaltrials |
| NCT00006365 | External-Beam Radiation Therapy Plus Implanted Radiation Therapy in Treating Patients With Prostate Cancer | completed | Phase 2 | 138 | Radiation Therapy Oncology GroupNETWORK | 2 | Oct 22, 2020 | clinicaltrials |
| NCT01899599 | PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer | completed | Phase 2 | 216 | Glycotope GmbHINDUSTRY | 8 | Oct 22, 2020 | clinicaltrials |
| NCT00391118 | Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill") | completed | Phase 2 | 153 | Eli Lilly and CompanyINDUSTRY | 5 | Oct 19, 2020 | clinicaltrials |
| NCT01498978 | Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 2 | 10 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT03515577 | Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery(PSMA vs AXUMIN) | completed | Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT03675451 | PSMA Imaging of Localized Prostate Cancer | completed | Phase 2 | 20 | Weill Medical College of Cornell UniversityOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT02064582 | Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer | completed | Phase 2 | 7 | University of Texas Southwestern Medical CenterOTHER | 1 | Oct 12, 2020 | clinicaltrials |
| NCT02560337 | Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy.(CaTo-ROC) | completed | Phase 2 | 26 | Vejle HospitalOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT01199263 | Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 108 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2020 | clinicaltrials |
| NCT01875250 | Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer | completed | Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2020 | clinicaltrials |
| NCT02059213 | A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer | completed | Phase 2 | 72 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 16, 2020 | clinicaltrials |
| NCT01266460 | Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 54 | Gynecologic Oncology GroupNETWORK | 1 | Sep 11, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Mar 5, 2021source: clinicaltrials